News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lux Biosciences Receives Acceptance of Luveniq(TM) MAA Filing from European Medicines Evaluation Agency



3/2/2010 11:04:16 AM

JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc. today announced that the European Medicines Agency (EMA) has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye. Lux previously announced the filing of both the MAA and U.S. New Drug Application (NDA) for LX211, which has received Orphan Drug designation in both regions, on February 4, 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES